To validate that KMT2A fusions not only bind to the promoter region but also directly affect DYRK1A transcription, we next analyzed ChIP-Seq data from the MOLM13 (KMT2A::MLLT3) AML cell line and the RS4;11 (KMT2A::AFF1) ALL cell line [10]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.